Resistant Bacteria in Children in France
Launched by ASSOCIATION CLINIQUE THÉRAPEUTIQUE INFANTILE DU VAL DE MARNE · Sep 7, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how new antibiotics can help treat infections caused by bacteria that are resistant to multiple medications in children. It aims to gather information on how these antibiotics work for kids who are hospitalized in France and suffering from serious infections. The researchers are particularly interested in understanding the effects of specific antibiotics on children's health and their recovery from these infections.
To participate in this study, children must be under 18 years old and currently admitted to a hospital that is part of the ACTIV/GPIP network in France. They should be receiving treatment with certain antibiotics for a documented infection, which can be confirmed through various tests like blood samples or other body fluids. If you choose to take part, you’ll help doctors learn more about how to better treat infections in children with resistant bacteria, but your child must be willing to participate, and some medical conditions may prevent participation. Overall, this trial is an important step toward improving treatment options for young patients facing challenging infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children under 18 years of age
- • Hospitalized in France in a hospital center working with the ACTIV/GPIP network
- * Treated with one or more of the following antibiotics:
- • Colimycin (Colistimethate sodium)
- • Cefiderocol
- • Aztreonam in combination
- • Ceftolozane-Tazobactam
- • Ceftazidime-avibactam
- • Meropenem/vaborbactam
- • Imipenem/Relebactam
- • Tigecycline
- • Daptomycin
- • Ceftaroline fosamil
- • Tedizolid phosphate
- • Fidaxomicin
- • Ceftobiprole
- • Dalbavancin
- In association with a documented infection performed by:
- • Blood culture
- • Normally sterile site
- • Cerebrospinal fluid
- • Pleural fluid
- • Pleura
- • Peritoneum
- • Joint fluid
- • Other
- • Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000)
- • Respiratory specimens if the bacteria was considered responsible for the infection
- • Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),....
- • Related to colonization with multidrug-resistant bacteria without documentation.
- Exclusion Criteria:
- • Refusal of participation by the patient or his/her parent
- • Medical history of mucoviscidosis
About Association Clinique Thérapeutique Infantile Du Val De Marne
The Association Clinique Thérapeutique Infantile du Val de Marne (ACTIV) is a dedicated clinical trial sponsor focused on advancing pediatric healthcare through innovative research and therapeutic interventions. Based in the Val de Marne region, ACTIV collaborates with healthcare professionals, academic institutions, and regulatory bodies to design and conduct clinical trials that address the unique medical needs of infants and children. With a commitment to ethical practices and patient safety, ACTIV aims to improve treatment outcomes and enhance the quality of life for young patients by translating scientific discoveries into effective clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Créteil, , France
Patients applied
Trial Officials
Levy Corinne
Study Director
Association Clinique Thérapeutique Infantile du val de Marne
Cohen Robert
Principal Investigator
Association Clinique Thérapeutique Infantile du val de Marne
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported